10 GLP-1 drug commercialization experts
Zepbound, Mounjaro, Ozempic, Rybelsus, Wegovy and oral semaglutide are the brands in the work of these GLP-1 drug commercialization experts: three marketers from Eli Lilly and Company, six from Novo Nordisk, and a former Novo Nordisk marketer now Global Commercial Lead GLP-1, Obesity at Sandoz. Their mix of global brand, lifecycle and country launch roles fits a drugmaker planning how to launch, position or extend a GLP-1 for diabetes or obesity.
Professionals to explore
Annika Bacchin-Bertling
LinkedInExperience: VP CVD Marketing & Launch · Novo Nordisk
Annika Bacchin-Bertling held VP Oral Semaglutide Diabetes Marketing at Novo Nordisk from 2022 to 2024 and Global Commercial Associate Director Oral Semaglutide Diabetes (2020-2021). Annika has been VP CVD Marketing & Launch at Novo Nordisk since 2024, and was Global Commercial Director CVD, Ziltivekimab in 2022, so oral semaglutide marketing and cardiovascular launch planning are both in range.
Is this you? Claim your profile and get paid for calls.
Fahad Nadeem Khan
LinkedInExperience: AVP Cardiometabolic Brand Strategy & Marketing · Novo Nordisk
Fahad Nadeem Khan was Global Marketing Vice President Diabetes GLP-1 & incretin pipeline at Novo Nordisk (2025-2026) and has been AVP Cardiometabolic Brand Strategy & Marketing there since 2026. Fahad also held Vice President Global Marketing Once-Weekly Insulin Portfolio (2024-2025) and Global commercial director (2022-2024), and cites lifecycle management across therapeutic areas over 14 years in pharma.
Is this you? Claim your profile and get paid for calls.
Haeseung Rha
LinkedInExperience: Director, Obesity BU(Wegovy Launched on 15th Oct 2024 & Saxenda) · Novo Nordisk
Haeseung Rha, based in Seoul, has been Director, Obesity BU(Wegovy Launched on 15th Oct 2024 & Saxenda) at Novo Nordisk since 2023, leading an obesity business unit with more than 90 sales staff across 10 teams. Haeseung also held oncology titles at AstraZeneca and Bristol Myers Squibb and was Toujeo Launch Leader of the insulin team at Sanofi (2015-2016).
Is this you? Claim your profile and get paid for calls.
Jian Dong
LinkedInExperience: Former Global Brand Director - Mounjaro · Eli Lilly and Company
Jian Dong held Global Brand Director - Mounjaro (2019-2022), Senior Director, Global Marketing - Mounjaro (2022-2023) and Executive Director, Obesity Global Marketing (2023-2024) at Eli Lilly and Company, and describes being part of the team behind Mounjaro, Zepbound and Trulicity. Jian has worked as a freelance Pharma Biotech Strategy Advisor since 2025, a fit for global brand and pipeline planning questions.
Is this you? Claim your profile and get paid for calls.
Kathrine Strand Nielsen
LinkedInExperience: Project Vice President, Semaglutide Projects · Novo Nordisk
Wegovy lifecycle management is Kathrine Strand Nielsen's current brief as Project Vice President, Semaglutide Projects at Novo Nordisk since 2022. Kathrine was Vice President, Obesity Strategy & Pipeline Projects (2021-2022) and Senior Global Director, Obesity Market Development (2018-2021) at Novo Nordisk, and held Director, Insulin marketing, Japan (2015-2018) and Director, Global Marketing, Ryzodeg (2012-2015).
Is this you? Claim your profile and get paid for calls.
Lasse Underbjerg
LinkedInExperience: Former Senior Global Director, Strategic Marketing, Obesity · Novo Nordisk
Lasse Underbjerg was Senior Global Director, Strategic Marketing, Obesity at Novo Nordisk (2025-2026), leading global digital strategy and consumer marketing ambition for the launch of Wegovy Pill, including direct-to-patient ecosystems and partnerships. Lasse was earlier Senior Global Director, Consumer Experience & Innovation, Obesity (2023-2025) and held design and innovation titles at Designit (2014-2023).
Is this you? Claim your profile and get paid for calls.
Miriam Beyer
LinkedInExperience: Global Commercial Lead GLP-1, Obesity · Sandoz
Miriam Beyer took the Global Commercial Lead GLP-1, Obesity role at Sandoz in 2026 after Medical & Marketing Director, CETA in BA East at Novo Nordisk Pharma Z o.o. (2025-2026). At Novo Nordisk Pharma GmbH, Miriam held Business Unit Director Diabetes and Obesity (2024-2025), Business Unit Director Obesity (2022-2024) and Marketing Manager GLP-1 (2018-2020), giving both Novo Nordisk and Sandoz views.
Is this you? Claim your profile and get paid for calls.
Oren Yellinek
LinkedInExperience: Global Commercial Associate Director · Novo Nordisk
Oren Yellinek's Novo Nordisk titles run from Product Manager, Ozempic (2018-2020) to Global Brand Lead, Ozempic (2020-2021) and Global Brand Lead, Rybelsus (2021-2023). Oren has been Global Commercial Associate Director at Novo Nordisk since 2023, based in Copenhagen, and is a fit for questions on positioning Ozempic and Rybelsus side by side.
Is this you? Claim your profile and get paid for calls.
Silvia Luque
LinkedInExperience: Former Executive Director, Zepbound Commercial Strategy · Eli Lilly and Company
Silvia Luque was Executive Director, Zepbound Commercial Strategy at Eli Lilly and Company (2022-2026) and Senior Director, HCP Marketing - US GLP-1 Diabetes (2021-2022). Since 2026, Silvia has been Head of US Marketing at Zealand Pharma, and earlier held Global Brand Director, Pre-launch, Diabetes at Lilly (2018-2019), with more than 13 years at the company building and launching brands.
Is this you? Claim your profile and get paid for calls.
Yossr Elgendy
LinkedInExperience: Associate Director - Mounjaro Obesity Marketing, Saudi Arabia, Bahrain, and Oman · Eli Lilly and Company
In Riyadh, Yossr Elgendy is Associate Director - Mounjaro Obesity Marketing, Saudi Arabia, Bahrain, and Oman at Eli Lilly and Company (since 2024), after Group Marketing Lead- Mounjaro Diabetes at the Saudi Arabia Regional Headquarter (2024) and Mounjaro Group Brand Manager -Launch Lead (2022-2023). Yossr earlier held marketing titles at Sanofi in Saudi Arabia and the GCC (2019-2022), which suits GCC launch questions.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For global brand strategy, Jian Dong, Oren Yellinek and Annika Bacchin-Bertling held global brand or marketing titles on Mounjaro, Ozempic, Rybelsus and oral semaglutide, and Kathrine Strand Nielsen covers Wegovy lifecycle management. Silvia Luque fits Zepbound commercial strategy and US marketing, Lasse Underbjerg consumer and direct-to-patient work, and Yossr Elgendy, Haeseung Rha and Miriam Beyer country and regional obesity and diabetes business roles.
Questions to take into the conversation
- 01How should a GLP-1 be positioned differently for type 2 diabetes and for obesity when the same molecule serves both?
- 02What decides whether to launch an oral GLP-1 alongside an injectable or hold it for a later lifecycle step?
- 03How do you plan GLP-1 launch volumes and payer access in a market where supply and reimbursement are both uncertain?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.